AI-based FFRangio software performs comparably to invasive pressure wire methods for evaluating coronary artery disease in a major international clinical trial.
Key Details
- 1FFRangio uses AI and 3D modeling from coronary angiograms to assess blood flow restrictions caused by artery plaques.
- 2The ALL-RISE trial enrolled 1,930 patients across five countries, comparing FFRangio with invasive wire-based pressure measurements.
- 3After one year, primary outcome events occurred in 6.9% of FFRangio patients versus 7.1% in the wire-based group.
- 4FFRangio is minimally invasive, faster, and eliminates the need for extra wires, catheters, or medication.
- 5The study was supported by CathWorks, Ltd., and results were published in the New England Journal of Medicine.
- 6Limitations include the trial not being blinded and exclusion of patients with prior coronary artery bypass surgery.
Why It Matters
This supports the viability of AI-driven imaging analysis as a less invasive, equally effective alternative to traditional procedures in coronary physiology assessment, potentially accelerating adoption and improving patient care efficiency in interventional cardiology.
Source
EurekAlert
Related News
•EurekAlert
AI and X-ray Imaging Reveal Lost Texts in Ancient Roman Scrolls
AI and x-ray technology enable scientists to virtually read previously unreadable, carbonized Roman scrolls from Herculaneum.
•EurekAlert
AI-Driven Blood Test Shows Success in Early Liver Cancer Detection Across Populations
Researchers validate an AI-powered cfDNA blood test that detects liver cancer accurately across diverse populations, enhancing early detection efforts.
•EurekAlert
AI Model Uses EKG and EHR Data to Predict Sudden Cardiac Arrest
Researchers have developed AI models that analyze EKG and EHR data to predict risk of sudden cardiac arrest in the general population.